Diabetic Peripheral Neuropathy (DPN) is of the most frequent complications encountered by diabetic patients. About 30 million US adults have diabetes. About 28.5% of diabetics suffer from DPN, and 40-50% of those patients suffer from painful DPN.​

Painful DPN is accompanied with tingling, throbbing, and stabbing pain. Currently approved medications for PDPN are palliative, only managing the pain, with possible serious side effects and can be highly addictive. Engensis (VM202) has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, not simply managing the pain.​

US FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation to VM202-DPN in 2018. This is first time in Korea, and the first and the only RMAT designation worldwide in pain area. Especially, Engensis is the first RMAT designated therapy in US of common diseases with over millions of patients. Engensis has been attracting huge attention in Painful DPN because of its big market size.